Skip to main content
×
×
Home

Treatment adherence therapy in people with psychotic disorders: randomised controlled trial

  • A. B. P. Staring (a1), M. Van der Gaag (a2), G. T. Koopmans (a3), J. P. Selten (a4), J. M. Van Beveren (a5), M. W. Hengeveld (a5), A. J. M. Loonen (a6) and C. L. Mulder (a7)...
Abstract
Background

Interventions to improve adherence to treatment in people with psychotic disorders have produced inconclusive results. We developed a new treatment, treatment adherence therapy (TAT), whose intervention modules are tailored to the reasons for an individual's non-adherence.

Aims

To examine the effectiveness of TAT with regard to service engagement and medication adherence in out-patients with psychotic disorders who engage poorly.

Method

Randomised controlled study of TAT v. treatment as usual (TAU) in 109 out-patients. Most outcome measurements were performed by masked assessors. We used intention-to-treat multivariate analyses (Dutch Trial Registry: NTR1159).

Results

Treatment adherence therapy v. TAU significantly benefited service engagement (Cohen's d = 0.48) and medication adherence (Cohen's d = 0.43). Results remained significant at 6-month follow-up for medication adherence. Near-significant effects were also found regarding involuntary readmissions (1.9% v. 11.8%, P = 0.053). Symptoms and quality of life did not improve.

Conclusions

Treatment adherence therapy helps improve engagement and adherence, and may prevent involuntary admission.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Treatment adherence therapy in people with psychotic disorders: randomised controlled trial
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Treatment adherence therapy in people with psychotic disorders: randomised controlled trial
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Treatment adherence therapy in people with psychotic disorders: randomised controlled trial
      Available formats
      ×
Copyright
Corresponding author
Anton B. P. Staring, Research Center O3, Erasmus MC University Medical Center, Department of Psychiatry, Trouwlaan 104, 5021 WN Tilburg, The Netherlands. Email: tonnie@backwash.org
Footnotes
Hide All

See editorial, pp. 431–432, this issue.

Funding for this study was provided by the Dutch Ministry of Health, Welfare, and Sports (ZonMw, research grant number 100-002-017).

Declaration of interest

None.

Footnotes
References
Hide All
1 Keath, SJ, Kane, JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003; 64:1308–15.
2 Thomas, P. The stable patient with schizophrenia–from antipsychotic effectiveness to adherence. Eur Neuropsychopharmacol 2007; 17 (suppl 2): s11522.
3 Weiden, P, Aquila, R, Standard, J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57 (suppl 11): s5360.
4 Fenton, WS, Blyer, C, Heinssen, RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23: 637–51.
5 Ucok, A, Polat, A, Cakir, S, Genc, A. One year outcome in first episode schizophrenia; predictors of relapse. Eur Arch Psychiatry Clin Neurosci 2006; 256: 3743.
6 Weiden, PJ, Kozma, C, Grogg, A, Locklear, J. Partial compliance and risk of rehospitalization among California medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886–91.
7 Hawton, K, Sutton, L, Haw, C, Sinclair, J, Deeks, JJ. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005; 187: 920.
8 Zygmunt, A, Olfson, M, Boyer, CA, Mechanic, D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002; 159: 1653–64.
9 Lincoln, TM, Wilhelm, K, Nestoriuc, Y. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophr Res 2007; 96: 2232–45.
10 Lecompte, D, Pelc, I. A cognitive-behavioral program to improve compliance with medication in patients with schizophrenia. Int J Ment Health 1996; 25:51–6.
11 Kemp, R, Kirov, G, Everitt, B, Hayward, P, David, A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 1998; 172:413–9.
12 Maneesakorn, S, Robson, D, Gournay, K, Gray, R. An RCT of adherenve therapy for people with schizophrenia in Chiang Mai, Thailand. J Clin Nurs 2007; 16: 1302–12.
13 Gray, R, Wykes, T, Edmonds, M, Leese, M, Gournay, K. Effect of a medication management training package for nurses on clinical outcomes for patients with schizophrenia. Cluster randomised controlled trial. Br J Psychiatry 2004; 185: 157–62.
14 O'Donnel, C, Donohoe, G, Sharkey, L, Owens, N, Migone, M, Harries, R, et al. Compliance therapy: a randomized controlled trial in schizophrenia. BMJ 2003; 327: 834–6.
15 Byerly, MJ, Fisher, R, Carmody, T, Rush, AJ. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005; 66: 9971001.
16 Gray, R, Leese, M, Bindman, J, Becker, T, Burti, L, David, A, et al. Adherence therapy for people with schizophrenia. European multicenter randomised controlled trial. Br J Psychiatry 2006; 189: 508–14.
17 National Institute for Health and Clinical Excellence (NICE). Schizophrenia; Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update). NICE, 2009 (http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf).
18 Staring, ABP, Mulder, CL, Van der Gaag, M, Selten, JP, Loonen, AJM, Hengeveld, MW. Understanding and improving treatment adherence in patients with psychotic disorders; a review and a proposed intervention. Curr Psychiatry Rev 2006; 2: 487–94.
19 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). APA, 1994.
20 Tait, L, Birchwood, M, Trower, P. A new scale (SES) to measure engagement with community mental health services. J Ment Health 2002; 11: 191–8.
21 World Health Organization. Composite International Diagnostic Interview (version 2.1 Auto). WHO, 1997.
22 Kikkert, MJ, Dekker, JJM, Koeter, MWJ, Schene, AH. The Inventory of Medication Intake (IMI): validation of an instrument for assessing adherence to antipsychotic medication. In Medication Adherence in Patients with Schizophrenia (ed Kikkert, MJ): 113–32. Dissertation at the University of Amsterdam, 2010.
23 Wing, JK, Beevor, AS, Curtis, RH, Park, SB, Hadden, S, Burns, A. Health of the Nation Outcome Scales (HoNOS). Research and development. Br J Psychiatry 1998; 172: 11–8.
24 Kikkert, MJ, Barbui, C, Koeter, MWJ, David, AS, Leese, M, Tansella, M, et al. Assessment of medication adherence in patients with schizophrenia. The achilles heel of adherence research. J Nerv Men Dis 2008; 196: 274–81.
25 Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76.
26 Staring, ABP, Mulder, CL, Duivenvoorden, HJ, De Haan, L, Van der Gaag, M. Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between entipsychotic medication compliance and quality of life. Schizophr Res 2009; 113: 2733.
27 Prieto, L, Sacristán, JA, Hormaechea, JA, Casado, A, Badía, X, Gómez, JC. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin 2003; 20: 827–35.
28 Lamers, LM, Stalmeier, PFM, McDonnell, J, Krabbe, PFM, Van Busschbach, JJ. Measuring the quality of life in cost-utility analyses: the Dutch EQ-5D tariff. Ned Tijdschr Geneeskd 2005; 149: 1574–8.
29 Birchwood, M, Smith, J, Drury, V, Healy, J, Macmillan, F, Slade, M. A self-report insight scale for psychosis: reliability, validity, and sensitivity to change. Acta Psychiatr Scand 1994; 89: 62–7.
30 Drayton, M, Birchwood, M, Trower, P. Early attachment experience and recovery from psychosis. Br J Psychol 1998; 37: 269–84.
31 Link, B, Struening, EL, Neese-Todd, S, Asmussen, S, Phelan, JC. On describing and seeking to change the experience of stigma. Psychiatr Rehabil Skills 2002; 6: 201–31.
32 Horvath, AO, Greenberg, LS. Development and validation of the working alliance inventory. J Consult Psychol 1989; 36: 223–33.
33 Cohen, J. Statistical Power Analysis for the Behavioral Sciences (2nd edn). Lawrence Erlbaum Associates, 1988.
34 O'Donoghue, B, Lyne, J, Hill, M, Larkin, C, Feeney, L, O'Callaghan, E. Involuntary admission from the patient's perspective. Soc Psychiatry Psychiatr Epidemiol 2010; 45: 631–8.
35 Valenstein, M, Kavanagh, J, Lee, T, Reilly, P, Dalack, GW, Grabowski, J, et al. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophr Bull 2009; Nov 21 (Epub ahead of print).
36 Hewitt, J, Coffey, M. Therapeutic working relationship with people with schizophrenia: literature review. J Adv Nurs 2005; 52: 561–70.
37 Staring, ABP, Van der Gaag, M, Van den Berge, M, Duivenvoorden, HJ, Mulder, CL. Stigma moderates the associations of insight with depressed mood, low self-esteem, and low quality of life in patients with schizophrenia spectrum disorders. Schizophr Res 2009; 115: 363–9.
38 Rathod, S, Kingdon, D, Smith, P, Turkington, D. Insight into schizophrenia: the effects of cognitive behavioural therapy on the components of insight and association with sociodemographics – data on a previously published randomised controlled trial. Schizophr Res 2005; 74: 211–9.
39 Claassen, D, Fakhoury, WK, Ford, R, Priebe, S. Money for medication: financial incentives to improve medication adherence in assertive outreach. Psychiatr Bull 2007; 31: 47.
40 Patel, MX, David, AS. Medication adherence: predictive factors and enhancement strategies. Psychiatry 2007; 6: 357–61.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 76 *
Loading metrics...

Abstract views

Total abstract views: 170 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 26th April 2018. This data will be updated every 24 hours.

Treatment adherence therapy in people with psychotic disorders: randomised controlled trial

  • A. B. P. Staring (a1), M. Van der Gaag (a2), G. T. Koopmans (a3), J. P. Selten (a4), J. M. Van Beveren (a5), M. W. Hengeveld (a5), A. J. M. Loonen (a6) and C. L. Mulder (a7)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *